Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

Cited In for PubMed (Select 16120823)


Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care.

De Nicola L, Provenzano M, Chiodini P, Borrelli S, Garofalo C, Pacilio M, Liberti ME, Sagliocca A, Conte G, Minutolo R.

PLoS One. 2015 May 20;10(5):e0127071. doi: 10.1371/journal.pone.0127071. eCollection 2015.


Inhibition of RAS in diabetic nephropathy.

Yacoub R, Campbell KN.

Int J Nephrol Renovasc Dis. 2015 Apr 15;8:29-40. doi: 10.2147/IJNRD.S37893. eCollection 2015. Review.


The Short-Term Remission of Diabetic Nephropathy After Roux-en-Y Gastric Bypass in Chinese Patients of T2DM with Obesity.

Zhang H, Di J, Yu H, Han X, Li K, Zhang P.

Obes Surg. 2015 Jul;25(7):1263-70. doi: 10.1007/s11695-015-1666-y.


Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome.

Leung KC, Pannu N, Tan Z, Ghali WA, Knudtson ML, Hemmelgarn BR, Tonelli M, James MT; APPROACH and AKDN Investigators.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1840-8. doi: 10.2215/CJN.03460414. Epub 2014 Oct 15.


Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease.

Kovesdy CP, Lu JL, Molnar MZ, Ma JZ, Canada RB, Streja E, Kalantar-Zadeh K, Bleyer AJ.

JAMA Intern Med. 2014 Sep;174(9):1442-9. doi: 10.1001/jamainternmed.2014.3279. Erratum in: JAMA Intern Med. 2014 Oct;174(10):1709.


Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.

Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, Kasiske BL, Wheeler DC, de Zeeuw D, Mogensen CE.

Kidney Int. 2015 Jan;87(1):20-30. doi: 10.1038/ki.2014.128. Epub 2014 Apr 30.


The impact of blood pressure on kidney function in the elderly: a cross-sectional study.

Zhang YP, Zuo XC, Huang ZJ, Kuang ZM, Lu MG, Duan DD, Yuan H.

Kidney Blood Press Res. 2013;38(2-3):205-16. doi: 10.1159/000355769. Epub 2014 Apr 9.


Systolic blood pressure and outcomes in stage 3-4 chronic kidney disease patients: evidence from a Taiwanese cohort.

Chiang HP, Lee JJ, Chiu YW, Tsai JC, Hung CC, Hwang SJ, Chen HC.

Am J Hypertens. 2014 Nov;27(11):1396-407. doi: 10.1093/ajh/hpu056. Epub 2014 Apr 11.


BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial.

Carpenter MA, John A, Weir MR, Smith SR, Hunsicker L, Kasiske BL, Kusek JW, Bostom A, Ivanova A, Levey AS, Solomon S, Pesavento T, Weiner DE.

J Am Soc Nephrol. 2014 Jul;25(7):1554-62. doi: 10.1681/ASN.2013040435. Epub 2014 Mar 13.


Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.

August P, Hardison RM, Hage FG, Marroquin OC, McGill JB, Rosenberg Y, Steffes M, Wall BM, Molitch M; BARI 2D Study Group.

Clin J Am Soc Nephrol. 2014 Jan;9(1):64-71. doi: 10.2215/CJN.12281211. Epub 2013 Oct 31.


The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: meta-analysis.

Toyama T, Furuichi K, Ninomiya T, Shimizu M, Hara A, Iwata Y, Kaneko S, Wada T.

PLoS One. 2013 Aug 30;8(8):e71810. doi: 10.1371/journal.pone.0071810. eCollection 2013.


Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.

Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M.

Diabetes Care. 2013 Nov;36(11):3460-8. doi: 10.2337/dc13-0323. Epub 2013 Sep 11.


The TRINITY Study: distribution of systolic blood pressure reductions.

Sugimoto DH, Chrysant SG, Melino M, Lee J, Fernandez V, Heyrman R.

Integr Blood Press Control. 2013 Jul 12;6:89-99. doi: 10.2147/IBPC.S45450. Print 2013.


Renal tissue oxygenation in essential hypertension and chronic kidney disease.

Pruijm M, Hofmann L, Vogt B, Muller ME, Piskunowicz M, Stuber M, Burnier M.

Int J Hypertens. 2013;2013:696598. doi: 10.1155/2013/696598. Epub 2013 Feb 20.


Inhibition of renin activity slows down the progression of HIV-associated nephropathy.

Kumar D, Plagov A, Yadav I, Torri DD, Sayeneni S, Sagar A, Rai P, Adabala M, Lederman R, Chandel N, Ding G, Malhotra A, Singhal PC.

Am J Physiol Renal Physiol. 2012 Sep;303(5):F711-20. doi: 10.1152/ajprenal.00643.2011. Epub 2012 Jun 20.


Long-term use and tolerability of irbesartan for control of hypertension.

Forni V, Wuerzner G, Pruijm M, Burnier M.

Integr Blood Press Control. 2011;4:17-26. doi: 10.2147/IBPC.S12211. Epub 2011 Apr 18.


Hemodynamic correlates of proteinuria in chronic kidney disease.

Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, Chen J, He J, Litbarg N, Ojo A, Rahman M, Rosen L, Sozio SM, Steigerwalt S, Strauss L, Joffe MM.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2403-10. doi: 10.2215/CJN.01670211. Epub 2011 Aug 18.


Diabetic nephropathy - Epidemiology in Asia and the current state of treatment.

Ritz E, Zeng X.

Indian J Nephrol. 2011 Apr;21(2):75-84. doi: 10.4103/0971-4065.82122. No abstract available.


Hypertension in chronic kidney disease: navigating the evidence.

Tedla FM, Brar A, Browne R, Brown C.

Int J Hypertens. 2011;2011:132405. doi: 10.4061/2011/132405. Epub 2011 May 24.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk